Fierce Pharma
AUGUST 6, 2024
Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. | Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.
MedCity News
AUGUST 6, 2024
The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business. The post Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 6, 2024
Warning of a "silent pandemic" spreading across the globe, Pfizer is taking the fight against antimicrobial resistance (AMR) Down Under. | Pfizer announced Tuesday that it has invested 150 million Australian dollars (about $98 million) to build a new manufacturing facility at its Australian site in Melbourne, where the company will help produce new antimicrobial treatments aimed at addressing the rising tide of antimicrobial resistance.
MedCity News
AUGUST 6, 2024
Apple Tree Partners’ latest startup is Red Queen Therapeutics, developer of stapled peptide drugs that block viral fusion. Its lead program is on track for Phase 2 testing in immunocompromised Covid-19 patients; a preclinical pan-influenza program is in development under a BARDA contract. The post Startup Red Queen Therapeutics Unveils $55M and Tech to Defeat Elusive Viral Pathogens appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 6, 2024
After previously floating the possibility of div | After previously floating the possibility of divesting Roctavian, BioMarin has decided to keep the hemophilia A gene therapy—but with a narrowed focus. The reorg comes with cost cuts across the medicine's R&D, manufacturing and commercialization support functions.
MedCity News
AUGUST 6, 2024
Blue Shield of California members can now access the Blue Zones Challenge App, which guides users to adopt the lifestyle habits of people in blue zones— regions known for longer, healthier lives. The post Blue Shield of California Offers Blue Zones App to Encourage Healthier Living appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
AUGUST 6, 2024
There's a new source of funding for life science companies, Symbiotic Capital, which is providing credit as an alternative to other financing routes
Fierce Pharma
AUGUST 6, 2024
Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year. | Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year.
pharmaphorum
AUGUST 6, 2024
Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.Agenus revealed BMS' decision in a Securities & Exchange Commission (SEC) filing (PDF), saying it was a result of a "broader strategic realignment of their development pipeline which involves other licensed products.
Fierce Pharma
AUGUST 6, 2024
Amid Bayer's massive reorganization, the company's pharma group is moving | The company plans to keep building out blockbuster hopeful Nubeqa, popular eye drug Eylea and newer Kerendia as its top-selling Xarelto succumbs to generic competition.
MedCity News
AUGUST 6, 2024
With so much to consider, avoiding hidden and often astronomical costs is a top priority for healthcare leaders. Understanding the totality of an EHR vendor’s offering is crucial, especially since vendors do not cover all the costs of their solutions similarly. The post Avoiding Surprises – Five Key Questions to Ask When Evaluating an EHR Vendor appeared first on MedCity News.
Fierce Pharma
AUGUST 6, 2024
Following a string of legal wins this year—plus one major setback in May—GSK has washed its hands of yet another lawsuit alleging the once-popular heartburn med Zantac can cause cancer. | GSK revealed in a statement Monday that it’s emerged victorious in Illinois state court after a jury determined that the company was not liable for a plaintiff’s colorectal cancer.
Pharmaceutical Commerce
AUGUST 6, 2024
ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.
MedCity News
AUGUST 6, 2024
With so many now seeking GLP-1 treatment, we must find ways to help providers care for more patients. Technology is the key to unlocking this capacity. The post Rising to the 100M Patient Challenge, Tech’s Role in Scaling Obesity Care appeared first on MedCity News.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
pharmaphorum
AUGUST 6, 2024
Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales but lower profits for the second quarter.Total revenues came in at €11.1 billion ($12.2 billion) in the quarter, ahead of analyst consensus estimates, with pharma leading the charge as it recorded sales up 4.5% to €4.61 billion.
Pharmaceutical Technology
AUGUST 6, 2024
Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.
MedCity News
AUGUST 6, 2024
Hospital finances seem to be stabilizing overall. However, a closer look reveals there is a widening gap between the highest- and lowest-performing hospitals, according to a new Kaufman Hall report. The post As Costs Continue to Grow, So Is the Gap Between High- and Low-Performing Hospitals appeared first on MedCity News.
Pharmaceutical Technology
AUGUST 6, 2024
GSK has announced the win in the latest trial concerning allegations that its heartburn medication Zantac was linked to cancer.
pharmaphorum
AUGUST 6, 2024
Novartis and Viatris are the latest pharma companies to be sued for allegedly profiting from the unlawful use of HeLa cells derived from Henrietta Lacks
Pharmaceutical Technology
AUGUST 6, 2024
The recent success of diabetes and weight loss medications has spurred more interest in other metabolic disorders.
Quantified
AUGUST 6, 2024
Stop Expecting New Hires to ‘Figure It Out’ – Invest in Training High turnover and poor performance are costly problems that stem from inadequate onboarding. Companies that fail to invest in proper training for new sales hires often face extended ramp-up times, lower productivity, and higher turnover rates. These issues can be mitigated with the right training programs, specifically by incorporating sales role – play and AI-driven coaching into new hire onboarding.
PharmaTimes
AUGUST 6, 2024
Neurological conditions, including Alzheimer’s disease, are the leading cause of ill health globally
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
AUGUST 6, 2024
Mallinckrodt agrees to sell Therakos to private equity firm CVC $925m, well below the $1.
PharmaTimes
AUGUST 6, 2024
Cardiovascular diseases currently affect around seven million people in the UK, including coronary heart disease
Pharmaceutical Technology
AUGUST 6, 2024
In the global pharmaceutical industry, there were 2 private equity deals announced in Q2 2024, worth a total value of $100m, according to GlobalData's Deals Database.
pharmaphorum
AUGUST 6, 2024
Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand therapy.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PM360
AUGUST 6, 2024
Unless patients have a voice right from product conception and design, new treatments could be poorly aligned with their needs, affecting take-up and commercial success. Unless patient considerations are central to the earliest stages of drug discovery and development—the premise of so-called Patient Focused Drug Development (PFDD)—new treatments or applications of a medicine could fail to make the grade.
PharmaTech
AUGUST 6, 2024
Pharmaceutical companies rely on and trust BD to provide consistent testing outcomes for their critical tests, with the tools they need to effectively monitor and control their manufacturing environment. From environmental monitoring, sterility testing and media fill results, there is a life connected.
PharmExec
AUGUST 6, 2024
The FINEARTS-HF study, which compared Kerendia to a placebo when added to standard therapy, met its primary endpoint by reducing cardiovascular death and total heart failure events.
PharmaTech
AUGUST 6, 2024
The new additions to the company’s equipment at its early phase clinical manufacturing facility in Oregon will allow for cleaning, filling, capping, and sealing, and also detecting defects in drug products.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
313 
Let's personalize your content